Physician profile
Mohanad Soliman
NPI 1942619408
$3,068.63
in general payments reported to CMS, 2019-2025
25 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $293 · 2023: $1,581 · 2024: $364 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.47 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $1,000.00 | 2023 | Irrisept |
| United Therapeutics Corporation | $580.65 | 2021-2023 | Orenitram, Remodulin, Tyvaso |
| Genzyme Corporation | $266.93 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $167.18 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $164.78 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Actelion Pharmaceuticals US, INC. | $111.36 | 2023 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $101.27 | 2023-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.27 | 2022-2025 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $78.27 | 2023-2025 | Verquvo |
| Pulmonx Corporation | $67.08 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Insmed, INC. | $62.71 | 2025 | Arikayce, Brinsupri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.30 | 2023-2025 | Lifevest |
| Mylan Specialty L.P. | $48.71 | 2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $38.76 | 2022-2025 | Glassia |
| Amgen INC. | $36.82 | 2024-2025 | Tezspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $34.54 | 2025 | Ohtuvayre |
| Getinge USA Sales, LLC | $27.85 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.01 | 2025 | Eliquis |
| Viatris Specialty LLC | $22.05 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $21.00 | 2025 | Ultomiris |
| Bracco Diagnostics INC. | $17.79 | 2025 | |
| Jazz Pharmaceuticals INC. | $14.72 | 2021 | |
| Grifols USA, LLC | $14.31 | 2025 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $13.86 | 2025 | Inspire |
| Olympus America INC. | $13.41 | 2023 | Evis Exera II Ultrasonic Bronchofibervideoscope |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohanad Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.